Northern Trust Corp Grows Stock Holdings in Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Northern Trust Corp raised its stake in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) by 4.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 251,930 shares of the company’s stock after buying an additional 11,812 shares during the period. Northern Trust Corp owned about 0.81% of Actinium Pharmaceuticals worth $317,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Vontobel Holding Ltd. purchased a new stake in Actinium Pharmaceuticals in the 4th quarter valued at about $32,000. Sei Investments Co. purchased a new stake in shares of Actinium Pharmaceuticals in the 4th quarter worth approximately $62,000. Creative Financial Designs Inc. ADV lifted its position in shares of Actinium Pharmaceuticals by 42.7% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 91,007 shares of the company’s stock worth $115,000 after purchasing an additional 27,222 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Actinium Pharmaceuticals by 804.5% in the 4th quarter. JPMorgan Chase & Co. now owns 123,831 shares of the company’s stock worth $156,000 after purchasing an additional 110,141 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Actinium Pharmaceuticals by 49.9% in the 4th quarter. Renaissance Technologies LLC now owns 190,400 shares of the company’s stock worth $240,000 after purchasing an additional 63,400 shares during the period. 27.50% of the stock is owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Stock Down 2.5%

NYSE:ATNM opened at $1.54 on Monday. Actinium Pharmaceuticals, Inc. has a 52 week low of $1.03 and a 52 week high of $8.64. The firm has a 50 day moving average of $1.46 and a 200 day moving average of $1.33. The stock has a market capitalization of $48.04 million, a price-to-earnings ratio of -1.11 and a beta of -0.24.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Actinium Pharmaceuticals in a research report on Monday, May 12th. Wall Street Zen cut shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Actinium Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $4.00.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).